Participation in a proficiency testing (PT) program is a valuable adjunct to laboratory activities dedicated to the maintenance of reliable analytical methods. The PT program may facilitate continuousquality improvement if laboratory performance is presented in the context of expectations espoused by healthcare professionalsfor optimal patient care. Statistical process control (SPC) and capabilityanalysis are tools used by industryin a Total Quality Management environment to characterize and monitor the performance of its processes relative to performance specifications. I conceptualized the use of an analytical system by many laboratories as a process that periodically produces resultsfrom the analysis of PT specimens. I treated a set of five PT results (theophytline)reported by a laboratory as a process sample and subjected the samples collected from many laboratories to SPC and capability analysis. The control charts--(X-bar) and s-charts--produced by the analysis readily identifysignificantanalytical errors in the contextof peer performanceand performance where the emphasis is to prevent defective work from being produced, as compared with inspection of the final product, where the objective is to remove defects after they have been produced. In SPC, product samples are drawn from the output stream and the variable of interest is measured.
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The sample is presumed to represent the properties of the process product and the measure of accuracy and precision is used to judge conformance to specifications.
If the sample ex-
ceeds control limits, the process is judged as unstable and action is taken to correct the problem before production of potentially defective products. 
where X is the overall average of laboratory z-values and ofV is the standard error of the mean. o-is an estimate of the process standard deviation and, by the postulates of sampling distributions,
301V is estimated
by A3s, where is the average standard deviation, and the coefficient A3 is a function of sample size obtained from tables of control chart constants (4) . The -chart control limits are determined as B4 and B3 where the coefficients are likewise dependent on sample size and are obtained from tables. The Statistica software automatically computes the process mean and control limits given the sampling data from the process. Because control limits are determined as 3 SEM, thereby encompassing 99.73% of the sample means from a stable process, we can assume that outliers occur not by chance, but by a special cause of variation.
Two sets of specification limits are recorded on the theophyllinei-chart:
PT limits and analytical goals for optimal patient care. The performance standard for the NYSDOH PT program is the recovery of theophyffine from test specimens to within 15% of the target value. The specification limits for PT are determined as X ± (l5%/CV), where X is the process mean z-value and CV is the process CV expressed as percent. The CV is estimated as the average CV of the five specimen data sets. A proposed analytical goal for the total allowable error in the determination of theophylline concentrations in serum is -9% (6). The i-chart specification limits for_optimal patient care, therefore, are determined as X ± (9%/CV). Given the specification limits, I used the Process Analysis module of Statistica to determine the capability of the respective analytical systems. The nominal value of the process (mean z-value) was set to zero and the capability index (C) was determined as (USL -LSL)/6o, where USL and LSL are, respectively, the upper and lower specification limits for proficiency testing or clinical requirements. A C >1.0 (desirable) signifies that >99.7% of the process's output will be within specification limits.
Results
The outcome of the SPC analysis is threefold: characterization of the capability of the analytical system to meet clinical and PT program specifications, characterization of each participant laboratory's performance relative to specifications and control limits established by peers, and characterization of outlier laboratory analytical error. This information is visualized from charts generated by the SPC analysis. dom error that exceeded the limits of system imprecision established by the performance of peers. These laboratories, regardless of the PT grade, should investigate the sources of special variation. The second step is the review of the distribution of sample means around the process mean in the i-chart (Fig. 1, top) Finally, if the sample mean exceeds the regulatory specification limit, the laboratory has failed the analyte PT challenge (laboratories 7, 71, and 136). All references to the interpretation of the i-chart presuppose that the standard deviation of laboratory results is within acceptable limits. Six of the seven laboratories that demonstrated excessive random error were within the specification limits on the i-chart (Fig. 1, top, circled The control limits for the -and -charts are determined from the overall variability of the method test results (from the central limit theorem, the SEM of means is s/V'i). The sample mean that exceeds the process limits (when the sample standard deviation is within limits) indicates a systematic error significantly greater than the inherent process variability. The three systems evaluated are calibration-stable devices for which the laboratory judges the need for recalibration from results for quality-control data. The systems are subjectto calibration drift, and the i-charts flagged systematic errors >3.8%, 5.4%, and 6.0% for the TDx, aca, and Ektachem, respectively, as exceeding limits of systematic error established by peer performance.
Clearly, laboratories flagged as exceeding the PT program specification limit (PT failure) will investigate and correct error sources. However, the i-chart provides useful feedback on the level of error relative to peers and specification limits, and laboratories so flagged can judge the need for correc- tive action based on the degree of departure from the nominal value and control limits.
An outcome of SPC that is lacking in conventional that are classified as special causes of variability.
However, my interest was to determine the C, for the analytical system, to reflect the performance of the method as it is used in the field. All laboratories included in this study are reporting test results to physicians, and a sampling of method output by analysis of PT specimens is presumed to reflect the quality of their analytical services. Only the TDx had a C >1.0 when calculated with the PT program specification limits of ±15% around the method mean. None of the analytical systems produced a C >1.0 for clinical specification limits. The C should prove to be a valuable statistic to characterize and monitor process performance.
Clearly, the limiting factor in processcapabifityisthe performance specification designed into the analytical system. I anticipate that the C for each analytical system will approach or exceed 1.0 as laboratories classified as special causes of variation identifythe sources of error and improve their performance.
The x-axis of control charts typically records the time sequence as samples are drawn from the process output. The charts can then be interpreted for process trends, shifts, and special causes of random error. SPC as I have applied it to PT data does not produce charts that are amenable to such interpretation. However, the charts may be useful to visualize differences in performance among categories of laboratories or among laboratories with identifiable characteristics. For example, physician's office laboratories, rural clinics, and tertiary-care centers can be grouped along the x-axis of the charts and the outcome of the SPC reviewed for relative analytical reliability. To illustrate the concept, I grouped laboratories participating in the NYSDOH PT program by the method of analysis for theophylline, selecting a random subset from the 175 TDx reports.
The data were transformed as (reported value -target value)/0.075(target value), where the target value is determined from the weighed amount of drug, and 2 [(0.075)(target value)] is the allowable error. The charts produced from this analysis are shown in Fig. 7 . Because the target value rather than the method mean is used in data transformation, the method bias from the nominal value may be an inherent method bias or be introduced by PT specimen- the level and type of error relative to peers, the device manufacturer can assess the capability of its system in the field, and the healthcare provider can easily discern how well the system meets needs for patients' care. The charts support activities of continuous improvement where, analogous to the Deming PDCA cycle (Plan, Do, Check, Act), the device manufacturer, the laboratory, healthcare providers, and regulatory agencies each has a role in defining performance specifications (planning), using the device according to accepted protocols (doing), monitoring device performance (checking), and responding to improve performance where it falls short of expectations (acting).
